A Gene Expression Test to Predict Prostate Cancer Aggressiveness

Use Prolaris® testing as a guide in your medical and surgical management

Prolaris
A prognostic medicine product for prostate cancer.
Prostate cancer (PCa) is now the second most frequently diagnosed cancer and the sixth most common cause of cancer-related mortality in men worldwide. An estimated 1.1 million men were diagnosed with prostate cancer across the world in 2012. Only 3% of men diagnosed with prostate cancer will die from it.

Prostate cancer natural history is highly variable and difficult to predict, with most men having indolent disease that could be safely followed without immediate treatment, and others having a more aggressive disease requiring immediate intervention.

Prolaris® (also called CCP in clinical publications) is the first prognostic test that offers a look inside the molecular biology of prostate cancer to help physicians determine its aggressiveness. In combination with other variables, such as Gleason score and PSA, Prolaris provides a personalized assessment of risk.

What is Prolaris®?

- A novel genetic test developed to help doctors predict prostate cancer aggressiveness, together with other clinical variables
- A direct molecular measure of prostate cancer tumor biology
- An RNA expression signature based on cell cycle progression (CCP) genes
- A 46 gene panel and integrative algorithms to assess prostate cancer aggressiveness
  - 31 genes across multiple cell cycle progression pathways
  - 15 housekeeper genes
- Prolaris testing results provide a Prolaris Score. Prolaris Scores can range from -3 to 7 (technical range). Each 1-unit increase in the Prolaris Score represents a doubling (or halving) of risk. Higher Prolaris Scores represent more aggressive cancers
- Prolaris testing can be done:
  - following affirmative biopsy and prostate cancer diagnosis
  - following radical prostatectomy
- Prolaris testing provides greater prognostic information than Gleason score or PSA
- Prolaris testing provides personalized risk assessment:
  - prognostic for biochemical recurrence (BCR), metastasis and PCa mortality

**The Prolaris 46-Gene Panel**

A prognostic medicine product for prostate cancer.

Prolaris® provides unique and independent information from current clinical and pathological features.
Prostate cancer (PCa) is now the second most frequently diagnosed cancer and the sixth most common cause of cancer-related mortality in men worldwide. An estimated 1.1 million men were diagnosed with prostate cancer across the world in 2012. Only 3% of men diagnosed with prostate cancer will die from it.

Prostate cancer natural history is highly variable and difficult to predict, with most men having indolent disease that could be safely followed without immediate treatment, and others having a more aggressive disease requiring immediate intervention.

Prolaris® (also called CCP in clinical publications) is the first prognostic test that offers a look inside the molecular biology of prostate cancer to help physicians determine its aggressiveness. In combination with other variables, such as Gleason score and PSA, Prolaris provides a personalized assessment of risk.

What is Prolaris®?

- A novel genetic test developed to help doctors predict prostate cancer aggressiveness, together with other clinical variables
- A direct molecular measure of prostate cancer tumor biology
- An RNA expression signature based on cell cycle progression (CCP) genes
- A 46 gene panel and integrative algorithms to assess prostate cancer aggressiveness
  - 31 genes across multiple cell cycle progression pathways
  - 15 housekeeper genes
- Prolaris testing results provide a Prolaris Score. Prolaris Scores can range from -3 to 7 (technical range). Each 1-unit increase in the Prolaris Score represents a doubling (or halving) of risk. Higher Prolaris Scores represent more aggressive cancers
- Prolaris testing can be done:
  - following affirmative biopsy and prostate cancer diagnosis
  - following radical prostatectomy
- Prolaris testing provides greater prognostic information than Gleason score or PSA
- Prolaris testing provides personalized risk assessment:
  - prognostic for biochemical recurrence (BCR), metastasis and PCa mortality

**THE PROLARIS 46-GENE PANEL**

<table>
<thead>
<tr>
<th>31 Cell Cycle Progression Genes</th>
<th>15 Housekeeper Genes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highly correlated and provide a reproducible measure of cell proliferation</td>
<td>Normalize the expression of the cell proliferation genes</td>
</tr>
</tbody>
</table>

Prolaris® provides unique and independent information from current clinical and pathological features.
Prolaris: Extensive Validation in both Biopsy and Radical Prostatectomy Settings

In a study of 349 conservatively managed prostate cancer patients diagnosed using needle biopsy, Prolaris Score™ was found to be the strongest independent predictor of prostate cancer-related death and provided more information than either Gleason score or PSA.6

A study of 582 patients evaluated the prognostic utility of the Prolaris Score derived from biopsy specimens in men who were treated by radical prostatectomy. Results from this study indicate that Prolaris can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.5

A study of 141 prostate cancer patients treated with external beam radiation therapy (EBRT) with curative intent evaluated whether Prolaris test can be used as a prognostic indicator. The study showed that Prolaris was significantly predictive of biochemical recurrence.6

Biopsy Setting

**BIOPSY SETTING**

**BIOPSY SETTING**

**BIOPSY SETTING**

**BIOPSY SETTING**

In **study** of 349 conservatively managed prostate cancer patients diagnosed using needle biopsy, Prolaris Score™ was found to be the strongest independent predictor of prostate cancer-related death and provided more information than either Gleason score or PSA.6

A study of 582 patients evaluated the prognostic utility of the Prolaris Score derived from biopsy specimens in men who were treated by radical prostatectomy. Results from this study indicate that Prolaris can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.5

A study of 141 prostate cancer patients treated with external beam radiation therapy (EBRT) with curative intent evaluated whether Prolaris test can be used as a prognostic indicator. The study showed that Prolaris was significantly predictive of biochemical recurrence.6

**BIOPSY SETTING**

**BIOPSY SETTING**

**BIOPSY SETTING**

**BIOPSY SETTING**

In a study of 349 conservatively managed prostate cancer patients diagnosed using needle biopsy, Prolaris Score™ was found to be the strongest independent predictor of prostate cancer-related death and provided more information than either Gleason score or PSA.6

A study of 582 patients evaluated the prognostic utility of the Prolaris Score derived from biopsy specimens in men who were treated by radical prostatectomy. Results from this study indicate that Prolaris can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.5

A study of 141 prostate cancer patients treated with external beam radiation therapy (EBRT) with curative intent evaluated whether Prolaris test can be used as a prognostic indicator. The study showed that Prolaris was significantly predictive of biochemical recurrence.6
Prolaris: Extensive Validation in both Biopsy and Radical Prostatectomy Settings

Prolaris has been validated in 11 clinical studies with more than 5,000 patients.

In a study of 349 conservatively managed prostate cancer patients diagnosed using needle biopsy, Prolaris Score™ was found to be the strongest independent predictor of prostate cancer-related death and provided more information than either Gleason score or PSA.¹

A study of 582 patients evaluated the prognostic utility of the Prolaris Score derived from biopsy specimens in men who were treated by radical prostatectomy. Results from this study indicate that Prolaris can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.²

A study of 141 prostate cancer patients treated with external beam radiation therapy (EBRT) with curative intent evaluated whether Prolaris test can be used as a prognostic indicator. The study showed that Prolaris was significantly predictive of biochemical recurrence.³

A study of 141 prostate cancer patients treated with external beam radiation therapy (EBRT) with curative intent evaluated whether Prolaris test can be used as a prognostic indicator. The study showed that Prolaris was significantly predictive of biochemical recurrence.⁴

Prolaris Score™ was found to be the strongest independent predictor of prostate cancer-related death and provided more information than either Gleason score or PSA.¹

A study of 582 patients evaluated the prognostic utility of the Prolaris Score derived from biopsy specimens in men who were treated by radical prostatectomy. Results from this study indicate that Prolaris can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.²

A study of 141 prostate cancer patients treated with external beam radiation therapy (EBRT) with curative intent evaluated whether Prolaris test can be used as a prognostic indicator. The study showed that Prolaris was significantly predictive of biochemical recurrence.³

Prolaris Score™ was found to be the strongest independent predictor of prostate cancer-related death and provided more information than either Gleason score or PSA.¹

A study of 582 patients evaluated the prognostic utility of the Prolaris Score derived from biopsy specimens in men who were treated by radical prostatectomy. Results from this study indicate that Prolaris can be used at disease diagnosis to better define patient prognosis and enable more appropriate clinical care.²

A study of 141 prostate cancer patients treated with external beam radiation therapy (EBRT) with curative intent evaluated whether Prolaris test can be used as a prognostic indicator. The study showed that Prolaris was significantly predictive of biochemical recurrence.³
A study of 366 patients showed that in patients who had undergone radical prostatectomy, a high Prolaris Score was predictive of Biochemical Recurrence (BCR). The Prolaris Score was predictive of death after disease progression and provided substantially more prognostic information than clinical variables alone. Prolaris was predictive of death after disease progression.  

Prolaris significantly modifies treatment decisions in prostate cancer:  

A prospective study evaluated the impact of the Prolaris testing on physician recommendations for Prostate Cancer Treatment. Clinicians ordering Prolaris test were asked how influential the test result was in making therapeutic decisions.  

A study of 413 patients concluded that Prolaris Score after radical prostatectomy provided independent prognostic information beyond clinico-pathological parameters and could be useful in helping guide decisions with respect to adjuvant treatment and in stratifying men for future adjuvant therapy studies.  

A study of 366 patients showed that in patients who had undergone radical prostatectomy, a high Prolaris Score was predictive of Biochemical Recurrence (BCR). The Prolaris Score was predictive of death after disease progression and provided substantially more prognostic information than clinical variables alone. Prolaris was predictive of death after disease progression.  

Prolaris adds Precisions to Conventional Risk Assessment  

• With AUA (D’Amico) risk categories alone, all patients within one group (low, intermediate or high risk) are assigned the same risk.  
• The addition of Prolaris Score will help physicians:  
  - Differentiate patients with similar AUA (D’Amico) risk profiles  
  - Better assess the near-term risk profile of patients  
  - Make more confident treatment decisions with patients.  

Prolaris® Further Stratifies Patients within Each AUA Biopsy Risk Category  

- The proportion of patients who develop biochemical recurrence at different follow-up times increases as the Prolaris (CCP) Score increases.

- In 65% of cases, there was a change recorded between the therapy initially planned and the therapy actually selected (40% decrease and 25% increase).
- In 40% of cases, clinicians indicated they would reduce the intended therapeutic burden post Prolaris test.
- In 88% of cases, the influence of Prolaris on therapeutic treatment recommendations was moderate to very high.

Based on the judgment of ordering physicians, the Prolaris Score adds meaningful new information to risk assessment for localized prostate cancer patients.

Prolaris® Further Stratifies Patients within Each AUA Biopsy Risk Category  

- The proportion of patients who develop biochemical recurrence at different follow-up times increases as the Prolaris (CCP) Score increases.

- In 65% of cases, there was a change recorded between the therapy initially planned and the therapy actually selected (40% decrease and 25% increase).
- In 40% of cases, clinicians indicated they would reduce the intended therapeutic burden post Prolaris test.
- In 88% of cases, the influence of Prolaris on therapeutic treatment recommendations was moderate to very high.

Based on the judgment of ordering physicians, the Prolaris Score adds meaningful new information to risk assessment for localized prostate cancer patients.

Prolaris® Further Stratifies Patients within Each AUA Biopsy Risk Category  

- The proportion of patients who develop biochemical recurrence at different follow-up times increases as the Prolaris (CCP) Score increases.

- In 65% of cases, there was a change recorded between the therapy initially planned and the therapy actually selected (40% decrease and 25% increase).
- In 40% of cases, clinicians indicated they would reduce the intended therapeutic burden post Prolaris test.
- In 88% of cases, the influence of Prolaris on therapeutic treatment recommendations was moderate to very high.

Based on the judgment of ordering physicians, the Prolaris Score adds meaningful new information to risk assessment for localized prostate cancer patients.
Prolaris adds Precision to Conventional Risk Assessment

• With AUA (D’Amico) risk categories alone, all patients within one group (low, intermediate or high risk) are assigned the same risk.

• The addition of Prolaris Score will help physicians:
  - differentiate patients with similar AUA (D’Amico) risk profiles
  - better assess the near-term risk profile of patients
  - make more confident treatment decisions with patients.

A study of 366 patients showed that in patients who had undergone radical prostatectomy, a high Prolaris Score was predictive of Biochemical Recurrence (BCR). The Prolaris Score was predictive of death after disease progression and provided substantially more prognostic information than clinical variables alone. Prolaris was predictive of death after disease progression.7

A study of 413 patients concluded that Prolaris Score after radical prostatectomy provided independent prognostic information beyond clinico-pathological parameters and could be useful in helping guide decisions with respect to adjuvant treatment and in stratifying men for future adjuvant therapy studies.8

Prolaris significantly modifies treatment decisions in prostate cancer:

A prospective study evaluated the impact of the Prolaris testing on physician recommendations for Prostate Cancer Treatment. Clinicians ordering Prolaris test were asked how influential the test result was in making therapeutic decisions.6

150 Clinicians Completed Surveys on the Influence of the Prolaris (CCP) Test in 305 Cases

<table>
<thead>
<tr>
<th>Change in Intended Therapeutic Options (pre-CCP Test to Post - CCP Test)</th>
<th>Total (n=305)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction</td>
<td>122 (40.0%)</td>
</tr>
<tr>
<td>No Change</td>
<td>107 (35.1%)</td>
</tr>
<tr>
<td>Increase</td>
<td>76 (24.9%)</td>
</tr>
</tbody>
</table>

- In 65% of cases, there was a change recorded between the therapy initially planned and the therapy actually selected (40% decrease and 25% increase).
- In 40% of cases, clinicians indicated they would reduce the intended therapeutic burden post Prolaris test.
- In 88% of cases, the influence of Prolaris on therapeutic treatment recommendations was moderate to very high.

Based on the judgment of ordering physicians, the Prolaris Score adds meaningful new information to risk assessment for localized prostate cancer patients.

Prolaris adds Precision to Conventional Risk Assessment

• With AUA (D’Amico) risk categories alone, all patients within one group (low, intermediate or high risk) are assigned the same risk.

• The addition of Prolaris Score will help physicians: differentiate patients with similar AUA (D’Amico) risk profiles better assess the near-term risk profile of patients make more confident treatment decisions with patients.
Prolaris® Benefits:

Prolaris® addresses a currently unmet need in prostate cancer by providing the clinician with direct information about prostate tumor aggressiveness that may be used to make more confident management decisions.

1. For example, at the time of diagnosis, a low Prolaris Score™ in the context of low-risk clinico-pathologic features may more accurately identify patients who are the best candidates for active surveillance.
2. Alternatively, a high Prolaris Score in patients with an intermediate risk profile may alter the management with additional staging and more aggressive (combination) therapy.

Prolaris also provides information that may be used to guide the extent of adjuvant treatment after primary therapy.

3. For example, a high Prolaris Score in the context of high-risk pathologic findings after radical prostatectomy may help identify patients who are appropriate candidates for adjuvant radiation.

“It seems certain that, particularly in men in whom the management approach is uncertain…there is a lot of information in this test to help you decide whether you need more aggressive therapy or can manage them more conservatively.”

Prof. Jack Cuzick, Queen Mary, University of London, UK

References:


A prognostic medicine product for prostate cancer.

Prolaris® testing assesses prostate cancer aggressiveness in conjunction with other clinical parameters. Prolaris® measures the expression level of genes involved with cell cycle progression (CCP) in tumor specimens to predict disease outcome.